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INDIVIDUAL CHARACTERISTICS INFLUENCE BLOOD 
PRESSURE RESPONSE TO ANTIHYPERTENSIVE DRUGS
Y. WU 1, T. BEJAN-ANGOULVANT 1, R. BOUSSAGEON 2, F. GUEYFFIER 1
1 Hospices Civils de Lyon ; CIC201-Inserm ; UMR5558-CNRS, Lyon, 
France
2 Département Médecine générale, UCBL, Lyon, France
Introduction — Antihypertensive treatment decreases 
cardiovascular risk mostly through blood pressure reduction. The 
current prescription strategy for the choice of drug between 
the  ve main antihypertensive classes relies upon intuitive or 
random choice by the physician. The objective of our analysis was 
to explore whether systolic blood pressure (SBP) reduction with 
diuretics, beta-blockers (BB), and calcium channel blockers (CCB), 
was related to the baseline individual characteristics, and quantify 
these potential associations.
Methods — We used data from 32767 patients recruited in  ve 
randomized placebo-controlled clinical trials in the INDANA 
database. The main outcome was the SBP fall (DSBP) between 
randomization and  rst follow-up visit. Multiple linear regression 
analyses were used to evaluate the relationship between DSBP, 
treatment, baseline characteristics of patients, and interactions 
between these covariates and treatment. Signi cance level of 
p<0.10 was used for all analyses.
Results — The average DSBP were 10, 8, 5 mmHg with diuretics, 
BB, and CCB classes respectively. Baseline SBP was signi cantly 
correlated to DSBP whatever the drug class. Age and baseline 
diastolic blood pressure were signi cantly correlated to DSBP for 
diuretics and BB, but not for CCB. With BB, height was positively 
correlated to DSBP, while smoking status was negatively correlated 
to DSBP.
Conclusion — Some individual characteristics explain a signi cant 
part of blood pressure reduction with drugs. These results will be 
integrated in algorithms to predict clinical bene t from these drugs.
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IMPACT DE LA TRANSPLANTATION RÉNALE SUR LA 
VÉLOCITÉ DE L’ONDE DE POULS
C. BACHELET-ROUSSEAU 1, A. KEARNEY-SCHWARTZ 2, L. FRIMAT 1, 
M. KESSLER 1, A. BENETOS 2
1 Département de néphrologie, Nancy, France
2 CIC-EC, Nancy, France
La maladie vasculaire du patient insuf sant rénal terminal est 
caractérisée par la coexistence de lésions d’athérosclérose 
et d’artériosclérose, cette dernière conduisant à une rigidité 
artérielle (RA). On sait que RA est un facteur indépendant de 
mortalité cardio-vasculaire chez le patient dialysé. Peu de données 
sont disponibles sur son évolution après transplantation rénale.
Objectifs — étudier l’évolution de la RA après transplantation 
rénale, dans une population de patients en IRCt, et la comparer à 
celle de patients restant en dialyse.
Matériel et Méthodes — 100 patients en IRCt candidats à une 
première transplantation ont été inclus, âge compris entre 35 
et 65 ans. Une première mesure de RA a été effectuée lors de 
l’inclusion, la deuxième 1 an après.
Résultats — l’âge moyen : 54 ± 7 ans, 35 patients ont été transplantés 
après un an de suivi. La VOP moyenne tendait à diminuer chez les 
transplantés entre les 2 visites (10.18 ± 3.41 m/s à V1, 9.90 ± 2.61 m/s 
à V2) sans différence signi cative, alors qu’elle restait stable chez les 
dialysés (10.62 ± 3.76 m/s à V1, 10.50 ± 3.61 m/s à V2). On constatait 
chez les transplantés une diminution signi cative des PAD et PAM 
périphériques (81 ± 13 mmHg à V1 vs 76 ± 10 mmHg à V2, 99 ± 14 
mmHg à V1 vs 94 ± 10 mmHg à V2) et centrales (80 ± 14 mmHg à V1 
vs 74 ± 10 mmHg à V2, 99 ± 14 mmHg à V1 vs 94 ± 09 mmHg à V2). 
La VOP post-greffe était signi cativement corrélée à la diminution de 
la PAM, n’était pas corrélée au degré de  ltration glomérulaire, au 
temps d’exposition après transplantation ou à l’âge du donneur. La 
diminution de la VOP était signi cativement corrélée à la diminution 
de la PAM.
Conclusion — dans cette étude, la diminution de la VOP corrélée 
à la diminution de la PAM suggèrerait un effet indirect possible 
de la transplantation sur l’évolution de la VOP. L’amélioration 
du pronostic cardio-vasculaire pourrait être expliquée chez les 
transplantés par la diminution des PAD et PAM périphériques et 
centrales après greffe.
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COMPARISON OF LENGTH-DEPENDENT CA2+ 
ACTIVATION OF CARDIAC MYOFILAMENTS BETWEEN 
THE RAT AND THE RAINBOW TROUT
S. PATRICK 1, H. SHIELS 1, O. CAZORLA 2
1 University of Manchester, Manchester, United Kingdom
2 Inserm U637, Montpellier, France
Most  sh regulate cardiac output via changes in stroke volume 
whereas most mammals regulate cardiac output via changes 
in heart rate. We hypothesized that this change in mechanism 
of regulation would coincide with a change in the myocardial 
response to stretch. This possibility was tested in permeabilized 
cardiomyocytes prepared from rat and rainbow trout ventricles, 
where both sarcomere length (SL) and degree of Ca2+ activation 
could be controlled. Myo lament Ca2+ sensitivity activation was 
higher in trout than in rat at each SL tested (2.0, 2.3, 2.5 and 2.7 ìm). 
We also found that permeabilized trout myocytes produce greater 
passive tension at any given SL than rat. This was surprising as the 
trout heart is known to be more compliant. Interestingly, addition 
of phosphatase inhibitors in the permeabilizing solution reduced 
passive tension in the trout cells suggesting that phosphorylation of 
titin may be important in determining passive tension in particular 
in trout heart. In conclusion contractile properties in trout seem 
highly sensitive to the length-dependent modulation.
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THE CAMP BINDING PROTEIN EPAC REGULATES 
CARDIAC MYOFILAMENT FUNCTION
O. CAZORLA 1, A. LUCAS 2, A. LACAMPAGNE 1, F. LEZOUALCH 2
1 Inserm U637, Montpellier, France
2 Inserm U769, Chatenay-Malabry, France
In the heart, cAMP is a key regulator of excitation—contraction 
coupling and its biological effects are mainly associated with the 
activity of protein kinase A (PKA). The aim of this study was to 
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investigate the contribution of the cAMP-binding protein Epac 
(Exchange protein directly activated by cAMP) in the regulation 
of the contractile properties of rat ventricular cardiac myocytes. 
We report that both PKA and Epac increased cardiac sarcomere 
contraction but through opposite mechanisms. Differently 
from PKA, selective Epac activation by the cAMP analog 8-pCPT 
reduced Ca2+ transient amplitude and increased cell shortening 
in intact cardiomyocytes as well as myo lament Ca2+ sensitivity 
in permeabilized cardiomyocytes. Moreover, ventricular myocytes, 
which were infected in vivo with a constitutively active form of 
Epac, showed enhanced myo lament Ca2+ sensitivity compared to 
control cells infected with GFP alone. At the molecular level, Epac 
increased phosphorylation of two key sarcomeric proteins, cardiac 
Troponin I (cTnI) and cardiac Myosin Binding Protein-C (cMyBP-C). 
The effects of Epac activation on myo lament Ca2+ sensitivity and 
on cTnI and cMyBP-C phosphorylation were independent of PKA, 
and were blocked by protein kinase C (PKC) and Ca2+ calmodulin 
kinase II (CaMKII) inhibitors. Altogether these  ndings identify Epac 
as a new regulator of myo lament function.
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HEMIN PREVENTS IN STENT RESTENOSIS IN RAT AND 
RABBIT MODELS: HEME OXYGENASE-1 AS A NEW 
THERAPEUTIC TARGET TO PREVENT RESTENOSIS
B. MAUREL 1, R. UZBEKOV 2, R. MOTTERLINI 3, P. LERMUSIAUX 1, 
J.-M. HYVELIN 1
1 Laboratoire de Physiopathologie de la Paroi Artérielle, EA3852, 
Faculté de Médecine, Université François Rabelais, Tours, France
2 Service de Biologie Cellulaire et Microscopie Electronique, 
Hôpital Bretonneau, CHRU de Tours, Tours, France
3 Department of Drug Discovery and Development, Italina 
Institute of Technology, Genova, Italy
Recent reviews have concluded that although drug eluting stent 
(DES) are ef cient in reducing in stent restenosis, their use does not 
have a signi cant effect on overall long-term survival as compared 
with bare metal stent. DES is associated with delayed vascular 
wall healing and endothelial function restoration, which mandates 
longer-term dual antiplatelet therapy. Recent studies demonstrated 
that the microsatellite polymorphism in the promoter of heme 
oxygenase-1 (HO-1) gene is related to angiographic restenosis. 
HO-1 is a rate-limiting enzyme in heme degradation ; leading to 
the generation of free iron, biliverdin, and carbon monoxide (CO). 
HO-1 is recognized to offer protection in many cardiovascular 
disorders. We aim to assess the potential protective effect of 
hemin, a potent HO-1 inducer, in the development of ISR in both 
rat and hypercholesterolemic rabbit.
In a rat model of aorta stenting and rabbit iliac stenting, chronic 
treatment with hemin (50 mg/kg/48h/ip) reduced neointima growth 
(-30 % and -50 % in hemin-treated rats and rabbits respectively), 
and most importantly stent struts remained covered, contrarily 
to the use of sirolimus eluting stent. Analysis of the cells facing 
the arterial lumen (electron microscopy) revealed an ultra-
structure similar to endothelial cells and the expression of CD31 
(immunogold labeling). Endothelial coverage was similar in hemin-
treated rats and greater in hemin-treated rabbits when compared 
to their control groups. Analysis of protein expression, in rats, 
revealed that hemin, limited the early in ammatory, apoptotic 
and proliferative cellular events common to ISR. More particularly, 
hemin treatment was associated with a decrease activity of key 
regulators of smooth muscle cell migration and proliferation, 
p42/44, RhoA and an increase of the expression of both cyclin 
dependent kinase inhibitors, p21 andp27kip1. This bene cial effect 
of hemin was abolished in presence of SnPP, an inhibitor of HO-1. 
Finally, CORM-3, a speci c carbon monoxide donor, limited ISR.
In conclusion, hemin reduced neointima growth without 
compromising re-endothelialization of the stented arteries. HO-1 
plays important role in limiting neointima growth, at least through 
the production of CO, and can be regarded as a new therapeutic 
target to prevent ISR.
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DARBEPOETIN-<ALPHA> PROTECTS HEART AGAINST 
ISCHEMIA-REPERFUSION: ROLE OF BCL-2 FAMILY 
PROTEINS
D. SCHLECHT-BAUER 1, D. ANTIER 1, M.-C. MACHET 1, J.-M. HYVELIN 1
1 Laboratoire de Physiopathologie de la Paroi Artérielle, EA3852, 
Faculté de Médecine, Université François Rabelais, 
Tours, France
Heart can usually survive a short period of ischemia, but when this 
period is too long, damages of the cardiac tissue became irreversible 
and are possibly exacerbated by blood reperfusion. Loss of cardiac 
myocytes via apoptosis is believed to contribute to the continuous 
decline of ventricular function described in heart failure. Limiting 
theses deleterious responses is of major importance in cardiac surgery 
and for the treatment of coronary thrombosis. The purpose of this 
study was to assess the short and long term cardioprotective effects 
of the long lasting effect erythropoietin analogue darbepoetin-α (DA) 
in a myocardial ischemia-reperfusion model in rat and ; to investigate 
the signaling pathway through which DA potentially limits apoptosis 
of cardiomyocytes.
Rat were subjected to 40 min left coronary artery ligation followed 
by 3h, 72 h or 4 weeks reperfusion and they received either DA 
(3 or 30 g/kg) or vehicle i.v. prior ischemia. Left ventricle (LV) 
function was assessed by echocardiography prior surgery and after 
reperfusion. Hearts were collected for histological analysis, protein 
analysis and reactive oxygen species (ROS) production.
In DA3 and DA30 72hrs groups, both LV shortening fraction and 
LV ejection fraction were higher vs. control (P<0.05), matching 
with histological analysis revealing a relative LV infarct size 72h 
post ischemia of 40 ± 5 % in control vs. 27 ± 3 and 17 ± 2 % in DA3 
and DA30, respectively. DA treatment lowered ROS production, 
the activity of caspase 3 in 3h and 72h reperfusion groups, and 
activated the JAK2/AkT signaling pathway and then increased both 
phosphorylated Bad and GSk3β proteins. This was consistent with 
the decrease of Bad-Bcl-Xl in DA30 group, suggesting an increased 
level of Bcl-Xl protein. Similar results were obtained in DA-treated 
rats reperfused 4 weeks ; in which cardiac  brosis was signi cantly 
lower than that in control group.
DA pre-treatment limited in a dose dependent manner the early 
and late I/R-induced heart injury in rat. Anti-apoptotic effects 
mediated through the activation the survival kinase Akt that 
regulates the Bcl-2 family proteins and activates GSK-3β is central 
in the DA cardioprotective mechanism.
